The mRNA-edited form of GABRA3 suppresses GABRA3-mediated Akt activation and breast cancer metastasis

Nature Communications

Volumn 7, Issue , 2016, Pages

  Gumireddy, Kiranmai ^a   Li, Anping ^a   Kossenkov, Andrew V ^a   Sakurai, Masayuki ^a   Yan, Jinchun ^b,c   Li, Yan ^d   Xu, Hua ^e   Wang, Jian ^f   Zhang, Paul J ^g   Zhang, Lin ^h   Showe, Louise C ^a   Nishikura, Kazuko ^a   Huang, Qihong ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA3; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; 4 AMINOBUTYRIC ACID A RECEPTOR; GABRA3 PROTEIN, HUMAN;

AMINO ACID; BRAIN; CANCER; CELLS AND CELL COMPONENTS; GENE; GENE EXPRESSION; INHIBITOR; RNA;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST METASTASIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MCF 7 CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; UPREGULATION; ANIMAL; BREAST TUMOR; CANCER STAGING; CANCER TRANSPLANTATION; CASE CONTROL STUDY; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; METABOLISM; METASTASIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RNA EDITING; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, GABA-A; RNA EDITING; RNA, MESSENGER;

EID: 84957998955     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10715     Document Type: Article

References (54)

1. Duran, C., Thompson, C. H., Xiao, Q. & Hartzell, H. C. Chloride channels: often enigmatic, rarely predictable. Annu. Rev. Physiol. 72, 95-121 (2010).
2. Watanabe, M. et al. Gamma-aminobutyric acid (GABA) and cell proliferation: focus on cancer cells. Histol. Histopathol. 21, 1135-1141 (2006).
3. A receptor trafficking and its role in regulating the plasticity of inhibitory synapses. Physiol. Rev. 91, 1009-1022 (2011).
4. Neman, J. et al. Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc. Natl Acad. Sci. USA 111, 984-989 (2014).
5. Bass, B. L. & Weintraub, H. A developmentally regulated activity that unwinds RNA duplexes. Cell 48, 607-613 (1987).
6. Rebagliati, M. R. & Melton, D. A. Antisense RNA injections in fertilized frog eggs reveal an RNA duplex unwinding activity. Cell 48, 599-605 (1987).
7. Bass, B. L. & Weintraub, H. An unwinding activity that covalently modifies its double-stranded RNA substrate. Cell 55, 1089-1098 (1988).
8. Wagner, R. W., Smith, J. E., Cooperman, B. S. & Nishikura, K. A double-stranded RNA unwinding activity introduces structural alterations by means of adenosine to inosine conversions in mammalian cells and Xenopus eggs. Proc. Natl Acad. Sci. USA 86, 2647-2651 (1989).
9. Nishikura, K. Editor meets silencer: crosstalk between RNA editing and RNA interference. Nat. Rev. Mol. Cell Biol. 7, 919-931 (2006).
10. Nishikura, K. Functions and regulation of RNA editing by ADAR deaminases. Annu. Rev. Biochem. 79, 321-349 (2010).
11. Hood, J. L. & Emeson, R. B. Editing of neurotransmitter receptor and ion channel RNA in the nervous system. Curr. Top. Microbiol. Immunol. 353, 61-90 (2012).
12. Kim, U., Wang, Y., Sanford, T., Zeng, Y. & Nishikura, K. Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc. Natl Acad. Sci. USA 91, 11457-11461 (1994).
13. Gerber, A., O'Connell, M. A. & Keller, W. Two forms of human double-stranded RNA-specific editase 1 (hRED1) generated by the insertion of an Alu cassette. RNA 3, 453-463 (1997).
14. Lai, F., Chen, C. X., Carter, K. C. & Nishikura, K. Editing of glutamate receptor B subunit ion channel RNAs by four alternatively spliced DRADA2 double-stranded RNA adenosine deaminases. Mol. Cell. Biol. 17, 2413-2424 (1997).
15. Melcher, T. et al. A mammalian RNA editing enzyme. Nature 379, 460-464 (1996).
16. Chen, C. X. et al. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA 6, 755-767 (2000).
17. Melcher, T. et al. RED2, a brain-specific member of the RNA-specific adenosine deaminase family. J. Biol. Chem. 271, 31795-31798 (1996).
18. Ohlson, J., Pedersen, J. S., Haussler, D. & Ohman, M. Editing modifies the GABA(A) receptor subunit alpha3. RNA 13, 698-703 (2007).
19. Heidenreich, B., Rachakonda, P. S., Hemminki, K. & Kumar, R. TERT promoter mutations in cancer development. Curr. Opin. Genet. Dev. 24, 30-37 (2014).
20. Sun, Y. et al. MiR-429 inhibits cell growth and invasion and regulates EMT-related marker genes by targeting Onecut 2 in colorectal carcinoma. Mol. Cell. Biochem. 390, 19-30 (2014).
21. Dunne, J. et al. AML1/ETO and POU4F1 synergy drives B-lymphoid gene expression typical of t(8;21) acute myeloid leukemia. Leukemia 26, 1131-1135 (2012).
22. Torisu, Y. et al. Human homologu of NOTUM, overexpression in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF. Cancer Sci. 99, 1139-1146 (2008).
23. Lader, M. H. & Morton, S. V. A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. J. Psychopharmacol. 6, 357-363 (1992).
24. Laurie, D. J., Wisden, W. & Seeburg, P. H. The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. J. Neurosci. 12, 4151-4172 (1992).
25. Poulter, M. O., Barker, J. L., O'Carroll, A. M., Lolait, S. J. & Mahan, L. C. Differential and transient expression of GABAA receptor alpha-subunit mRNAs in the developing rat CNS. J. Neurosci. 12, 2888-2900 (1992).
26. A) receptor. J. Biol. Chem. 286, 2031-2040 (2011).
27. McCubrey, J. A. et al. Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. Adv. Biol. Regul. 57, 75-101 (2015).
28. Martini, M., De Santis, M. C., Braccini, L., Gulluni, F. & Hirsch, E. PI3K/AKT signaling pathway and cancer: an updated review. Ann. Med. 46, 372-382 (2014).
29. Davis, N. M. et al. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget 2, 4603-4650 (2014).
30. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003).
31. Chaffer, C. L. et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA 108, 7950-7955 (2011).
32. Stepulak, A. et al. Expression of glutamate receptor subunits in human cancer. Histochem. Cell Biol. 132, 435-445 (2009).
33. Wangari-Talbot, J., Wall, B. A., Goydos, J. S. & Chen, S. Functional effects of GRM1 suppression in human melanoma cells. Mol. Cancer Res. 10, 1440-1450 (2012).
34. Lee, H. J. et al. Glutamatergic pathway targeting in melanoma; single agent and combinatorial therapies. Clin. Cancer Res. 17, 7080-7092 (2011).
35. Yip, D. et al. A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin. Cancer Res. 15, 3896-3902 (2009).
36. Crestani, F. & Rudolph, U. Behavioral functions of GABAA receptor subtypes - the Zurich experience. Adv. Pharmacol. 72, 37-51 (2015).
37. Fritschy, J. M. & Panzanelli, P. GABAA receptors and plasticity of inhibitory neurotransmission in the central nervous system. Eur. J. Neurosci. 39, 1845-1865 (2014).
38. Mohler, H. The legacy of the benzodiazepine receptor: from flumazenil to enhancing cognition in Down syndrome and social interaction in autism. Adv. Pharmacol. 72, 1-36 (2015).
39. Martini, M., De Santis, M. C., Braccini, L., Gulluni, F. & Hirsch, E. PI3K/AKT signaling pathway and cancer: an updated review. Ann. Med. 46, 372-383 (2014).
40. Zhou, H. & Huang, S. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr. Protein Pept. Sci. 12, 30-42 (2011).
41. Zhou, J. et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl Acad. Sci. USA 104, 16158-16163 (2007).
42. Wu, W. et al. Linking g-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer. Mol. Cell. Endocrinol. 383, 69-79 (2014).
43. Park, H. S. et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod. Pathol. 27, 1212-1222 (2014).
44. O'Hurley, G. et al. Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. Histopathology 64, 660-670 (2014).
45. Yang, W., Wang, Q., Kanes, S. J., Murray, J. M. & Nishikura, K. Altered RNA editing of serotonin 5-HT2c receptor induced by interferon: implications for depression associated with cytokine therapy. Brain Res. Mol. Brain Res. 124, 70-78 (2004).
46. Patterson, J. B. & Samuel, C. E. Expression and regulation by interferon of a double-stranded RNA specific adenosine deaminase from Human cells: evidence for two forms of the deaminase. Mol. Cell. Biol. 15, 5376-5388 (1995).
47. George, C. X., Wagner, M. V. & Samuel, C. E. Expression of interferon-inducible RNA adenosine deaminase ADAR1 during pathogen infection and mouse embryo development involves tissue-selective promoter utilization and alternative splicing. J. Biol. Chem. 280, 15020-15028 (2005).
48. Carpi, A., Nicolini, A., Antonelli, A., Ferrari, P. & Rossi, G. Cytokines in the management of high risk or advanced breast cancer: an update and expectation. Curr. Cancer Drug Targets 9, 888-903 (2009).
49. Recchia, F. et al. Beta-interferon, retinoids and tamoxifen in metastatic breast cancer: long-term follow-up of a phase II study. Oncol. Rep. 21, 1011-1016 (2009).
50. Nicolini, A. & Carpi, A. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. Biomed. Pharmacother. 59, 253-263 (2005).
51. Gumireddy, K. et al. ID1 promotes breast cancer metastasis by S100A9 regulation. Mol. Cancer Res. 12, 1334-1343 (2014).
52. Gumireddy, K. et al. Identification of a long noncoding RNA-associated RNP complex regulating metastasis at the translational Step. EMBO J. 32, 2672-2684 (2013).
53. Gumireddy, K. et al. KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat. Cell Biol. 11, 1297-1304 (2009).
54. Huang, Q. et al. The microRNAs miR-373 and miR-520c promote tumor invasion and metastasis. Nat. Cell Biol. 10, 202-210 (2008).